News | July 05, 2023
Venus Remedies gets marketing approvals for oncology medicine from 4 key markets
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
This request for withdrawal of the two dossiers was made after necessary consultations and receiving guidance from EMA
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
Pre-filled pens containing a combination of insulin glargine 100 Units/mL and lixisenatide for once-daily dosing
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
Themis will market this drug with the brand name REMITHEM.
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
Subscribe To Our Newsletter & Stay Updated
